Foghorn Therapeutics Management
Management criteria checks 2/4
Foghorn Therapeutics' CEO is Adrian H. Gottschalk, appointed in May 2017, has a tenure of 7.58 years. total yearly compensation is $2.50M, comprised of 23.1% salary and 76.9% bonuses, including company stock and options. directly owns 0.92% of the company’s shares, worth $2.63M. The average tenure of the management team and the board of directors is 1.3 years and 7.4 years respectively.
Key information
Adrian H. Gottschalk
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 23.1% |
| CEO tenure | 7.6yrs |
| CEO ownership | 0.9% |
| Management average tenure | 1.3yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk
Oct 22Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up
Sep 01Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking
Jul 17Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 09Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$91m |
| Jun 30 2024 | n/a | n/a | -US$86m |
| Mar 31 2024 | n/a | n/a | -US$93m |
| Dec 31 2023 | US$3m | US$579k | -US$98m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$115m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$5m | US$575k | -US$109m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$105m |
| Dec 31 2021 | US$4m | US$540k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$93m |
| Jun 30 2021 | n/a | n/a | -US$85m |
| Mar 31 2021 | n/a | n/a | -US$78m |
| Dec 31 2020 | US$3m | US$479k | -US$69m |
| Sep 30 2020 | n/a | n/a | -US$63m |
| Jun 30 2020 | n/a | n/a | -US$58m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$1m | US$465k | -US$51m |
Compensation vs Market: Adrian H.'s total compensation ($USD2.50M) is above average for companies of similar size in the US market ($USD1.41M).
Compensation vs Earnings: Adrian H.'s compensation has been consistent with company performance over the past year.
CEO
Adrian H. Gottschalk (48 yo)
7.6yrs
Tenure
US$2,503,942
Compensation
Mr. Adrian H. B. Gottschalk serves as President, Chief Executive Officer and a Director of Foghorn Therapeutics Inc. since May, 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Bioge...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.6yrs | US$2.50m | 0.92% $ 2.6m | |
| Chief Scientific Officer | 2.9yrs | US$1.19m | 0.27% $ 781.1k | |
| Chief Medical Officer | 1.3yrs | US$1.84m | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief of Staff to the CEO | less than a year | no data | no data | |
| Chief Legal Officer | 4.1yrs | US$1.99m | 0% $ 0 | |
| Vice President of Corporate Development | 2.9yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| VP & Chief of Staff Research | less than a year | no data | no data |
1.3yrs
Average Tenure
52yo
Average Age
Experienced Management: FHTX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.6yrs | US$2.50m | 0.92% $ 2.6m | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | US$157.65k | 0% $ 0 | |
| Independent Director | 7.4yrs | US$159.07k | 0.061% $ 175.1k | |
| Founder & Independent Chairman of the Board | 9.2yrs | US$184.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.4yrs | US$153.07k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$154.57k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$145.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2.3yrs | US$252.52k | 6.52% $ 18.6m |
7.4yrs
Average Tenure
65yo
Average Age
Experienced Board: FHTX's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 11:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Foghorn Therapeutics Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Etzer Darout | BMO Capital Markets Equity Research |
| Gavin Clark-Gartner | Evercore ISI |